Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
Public ClinicalTrials.gov record NCT00461396. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-Label, Multicenter, Observational, Phase IV Study to Evaluate the Adherence to Treatment With 250mcg (8MIU) IFNB-1b (Betaseron®) Given Subcutaneous Every Other Day Over a Period of up to 12 Months in Patients With a First Clinical Demyelinating Event Suggestive of Multiple Sclerosis and Patients With Onset of Relapsing-Remitting Multiple Sclerosis (RRMS) Within the Past 12 Months
Study identification
- NCT ID
- NCT00461396
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 104 participants
Conditions and interventions
Interventions
- Interferon-1beta (Betaseron, BAY86-5046) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2007
- Primary completion
- May 31, 2009
- Completion
- Oct 31, 2009
- Last update posted
- Apr 7, 2011
2007 – 2009
United States locations
- U.S. sites
- 19
- U.S. states
- 19
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Many Locations | Alabama | — | — |
| Not listed | Many Locations | Arizona | — | — |
| Not listed | Many Locations | Delaware | — | — |
| Not listed | Many Locations | District of Columbia | — | — |
| Not listed | Many Locations | Florida | — | — |
| Not listed | Many Locations | Georgia | — | — |
| Not listed | Many Locations | Illinois | — | — |
| Not listed | Many Locations | Iowa | — | — |
| Not listed | Many Locations | Louisiana | — | — |
| Not listed | Many Locations | Maine | — | — |
| Not listed | Many Locations | Minnesota | — | — |
| Not listed | Many Locations | Missouri | — | — |
| Not listed | Many Locations | New Jersey | — | — |
| Not listed | Many Locations | New York | — | — |
| Not listed | Many Locations | North Carolina | — | — |
| Not listed | Many Locations | Ohio | — | — |
| Not listed | Many Locations | Pennsylvania | — | — |
| Not listed | Many Locations | Tennessee | — | — |
| Not listed | Many Locations | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00461396, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 7, 2011 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00461396 live on ClinicalTrials.gov.